Developer docs
API playgroundTry for free, no card

Search company profiles

Geneial

Full company profile

uuid0002ydx

Namestring
Geneial
Legal namestring
Geneial Inc.
Websiteurl
geneial.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Geneial is a Houston, Texas-based health technology company, founded in 2020, that operates a privacy-preserving, decentralized rare disease registry platform connecting patient advocacy groups, academic researchers, and pharmaceutical companies. The company targets the rare disease research market, which encompasses more than 7,000 known conditions affecting roughly 300 million people worldwide, where fewer than 5% have FDA-approved treatments and natural history studies are increasingly required for orphan drug development. Geneial's registries already span 30+ countries and cover 10+ rare diseases, anchored by deployments with the Xia-Gibbs Society (30 countries, 240+ participants) and the HNRNP Family Foundation (an umbrella registry for 10 neurodevelopmental disorders). The company is led by CEO Dr. Adam Hansen and remains privately held with no public revenue disclosure.

The platform is built on two core products and a set of AI modules. Bridge is the registry management interface for researchers and registry managers, offering a survey builder, 21 CFR Part 11-compliant eConsent, participant enrollment tracking, cohort analysis, public statistics dashboards, and bidirectional REDCap integration that allows organizations to upgrade from REDCap without data migration. Advocate is an iOS and Android mobile application for patient communities built around four pillars: Knowledge, Community, Care, and Control, with two-way sync into Bridge. The platform is reinforced by open-source AI tools: GenOMA (an agentic ontology mapping pipeline that converts patient-reported free-text into HPO, SNOMED, and ICD-10 codes with F1 ~0.96), the Geneial Transform Agent (data transformation to GA4GH Phenopackets and LinkML), a UMLS Server for high-performance biomedical terminology access, and synTOPia for privacy-preserving synthetic data generation. Infrastructure is HIPAA, 21 CFR Part 11, SOC 2 Type I, and GDPR compliant and includes a fully homomorphic encryption API for cross-registry queries.

Geneial's commercial model is tiered SaaS subscriptions (Community free, Pro custom-priced, Enterprise custom-priced) with a community-led go-to-market anchored in patient advocacy groups, supplemented by enterprise sales to pharma, CROs, and large academic institutions. A free Contact Registry tier launched in October 2025 extends a product-led growth motion into newly forming advocacy organizations. To date, the company has operated primarily on non-dilutive NIH SBIR funding totaling approximately $2.7M, with strategic relationships including Baylor College of Medicine's Human Genome Sequencing Center, NIH (NHGRI and NHLBI), ARPA-H, RENCI, and a non-binding LOI with NASDAQ-listed Lunai Bioworks.

Short descriptiontext

Geneial is a Houston-based health technology company that operates a privacy-preserving rare disease registry platform with bidirectional REDCap integration, AI-powered ontology mapping, and mobile patient engagement, serving patient advocacy groups, academic researchers, and pharma/CROs across 30+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease registries, patient registry platform, clinical data management, biomedical data standardization, health data interoperability
Industry4 codes
PRIMARYHLACAIAH
Clinical Data Repositories (CDR) & Longitudinal Patient Records
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare Data Platforms, Warehousing & Governance
SECONDARYHLACAIAG
Consent, Preference & Data Rights Management (incl. HIPAA/GDPR support)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare Data Platforms, Warehousing & Governance
SECONDARYHLACAIAI
FHIR/HL7 Data Repositories & Canonical Data Models
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare Data Platforms, Warehousing & Governance
SECONDARYHLAAANAL
Population Genomics & Preventive Precision Health Programs
NAICS code2 codes
  • Custom Computer Programming Services541511
  • Computer Systems Design and Related Services54151
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Computer Programming, Data Processing, Etc.7370
Product category
Rare Disease Registry Platform
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1SaaS Platform Subscriptions (Community, Pro, Enterprise)
TypeSubscription Recurring
Description

Geneial generates revenue through tiered SaaS subscription plans. The Community tier is free for organizations starting their first registry. The Pro tier (custom pricing) includes full registry capabilities, REDCap integration, eConsent, unlimited users, and priority support. The Enterprise tier adds dedicated support, custom integrations, advanced analytics, and SLA. Annual billing is implied by custom pricing and demo-first sales motion.

geneial.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Pricing details3 tiers
1Free tier for patient advocacy organizations starting their first registry
ModelFreemiumBilling cadenceMonthly
Notes

Free Community tier includes: Advocate mobile app, powerful data grid, basic registry dashboard, HIPAA-compliant storage, standardized survey instruments, variant curation, up to 2 Bridge users per registry, community support. Coming soon: limited customization.

geneial.com
2Custom-priced tier for organizations running active registries with advanced needs
ModelSubscriptionBilling cadenceAnnual
Notes

Pro tier (custom pricing) includes everything in Community plus: custom survey instruments, unlimited Bridge users, bring your own IRB protocol, eConsent (21 CFR Part 11), custom consent documents, REDCap backend integration, import pre-existing data, gene map, clinician-filled surveys, repeat surveys, cohort analysis, custom onboarding, priority support. Coming soon: use Geneial's IRB protocol.

geneial.com
3Custom enterprise tier for multi-site studies and organizations with complex needs
ModelSubscriptionBilling cadenceAnnual
Notes

Enterprise tier includes everything in Pro plus: dedicated support, custom integrations, advanced analytics, SLA.

geneial.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 6 records shown
1Bridge
Description

Registry command center for building surveys, managing consent, tracking enrollment, and standardizing data. Features include registry builder, eConsent, and statistics dashboard.

geneial.com
+5 more records
Core offering1 text field

Geneial provides a privacy-preserving, decentralized rare disease registry platform consisting of Bridge (a registry management platform for researchers with survey builder, eConsent, cohort analysis, and stats dashboards) and Advocate (a patient-facing mobile app with Knowledge, Community, Care, and Control pillars). The platform integrates bidirectionally with REDCap, enforces HIPAA, 21 CFR Part 11, SOC 2 Type I, and GDPR compliance, and is augmented by proprietary AI tools (GenOMA ontology mapping, Transform Agent, UMLS Server, synTOPia synthetic data) that standardize patient-reported data to FAIR-compliant formats such as GA4GH Phenopackets and HPO codes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Registry deployment reduced from months to under one week using enhanced GenomeConnect survey with conditional logic and free-text fields
+4 more records
Product overview1 text field

Geneial offers a platform-plus-modules architecture for rare disease registries consisting of two core products: Bridge (registry management platform for researchers/registry managers) and Advocate (mobile app for patient communities). These are complemented by AI Tools including GenOMA (ontology mapping agent), Transform Agent (data transformation), UMLS Server (terminology access), and synTOPia (synthetic data generation). The platform supports REDCap integration with bidirectional data sync, enabling organizations to upgrade from REDCap without migration. Pricing tiers include Community (free), Pro (custom), and Enterprise (custom).

Product and service2 records
1Bridge
CategoryRegistry Management Platform
Description

Registry management platform for researchers and registry managers. Provides survey builder, eConsent (21 CFR Part 11), participant enrollment tracking, cohort analysis, HPO/HGVS code mapping, variant visualization, and stats dashboards. Integrates bidirectionally with REDCap and supports FAIR-compliant data standards.

2Advocate
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-16
Description

BioSymetrics (wholly owned subsidiary of NASDAQ-listed Lunai Bioworks) signed a non-binding LOI with Geneial for a strategic collaboration focused on rare neurological disorders. The collaboration aims to convert fragmented patient-generated data into trial-ready cohorts for pharmaceutical partnerships. Data across multiple patient registries and longitudinal clinical data will be integrated to support cohort development and translational research. Specific commercial terms to be defined in future definitive agreements.

2HNRNP Family Foundation
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-05
Description

HNRNP Family Foundation partnered with Geneial for an umbrella registry covering 10 HNRNP-Related Neurodevelopmental Disorders (HNRNP-RNDDs). The partnership enables collection, curation, and analysis of complex data across multiple genes, research sites, and data sources. Geneial's team also supported the foundation in writing grant applications, demonstrating deep collaborative partnership beyond software provision.

geneial.com
Strategic tierCoreTypeOthersAnnounced on2023-11-01
Description

Geneial received NIH funding through multiple grants: $2.3M SBIR grant (September 2022, NHGRI), Phase II SBIR grant (July 2023), and Phase I SBIR award for pharmacogenomics platform (November 2023). Total NIH funding exceeds $2.7M. NIH grants fund development of privacy-preserving, decentralized platform for genetic disease research and pharmacogenomics applications.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-11-01
Description

Geneial was awarded a one-year pilot project through NHLBI BioData Catalyst (BDC) program and RENCI to partner with ARPA-H Biomedical Data Fabric (BDF) Toolbox program. Collaboration aims to advance AI tools that automate transformation of biomedical data into analysis-ready formats, supporting GA4GH Phenopackets standards. CEO Dr. Adam Hansen noted the partnership directly addresses data standardization bottlenecks in precision medicine.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-11-01
Description

RENCI collaborates with Geneial on a one-year pilot project through NHLBI BioData Catalyst program, partnering with ARPA-H. RENCI develops and deploys advanced technologies to enable research discoveries. The collaboration focuses on AI-driven biomedical data standardization at scale.

6NHLBI BioData Catalyst (BDC)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-11-01
Description

National Heart, Lung, and Blood Institute's BioData Catalyst program awarded Geneial a one-year pilot project alongside RENCI and ARPA-H to advance AI tools for biomedical data standardization and interoperability.

prnewswire.com
7Xia-Gibbs Society
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-26
Description

Xia-Gibbs Society deployed Geneial Bridge and Advocate for their global rare disease community. The society, led by Executive Director Greg Wilkinson, manages a registry spanning 30 countries covering families affected by Xia-Gibbs Syndrome (AHDC1 gene variants). Geneial replaced a REDCap-based system managed by Baylor College of Medicine HGSC.

geneial.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-12
Description

Geneial partnered with BCM-HGSC led by Dr. Richard Gibbs to establish a proof-of-concept for privacy-preserving data exchange using the Xia-Gibbs Syndrome registry. Successfully demonstrated advanced encryption enabling exact-match querying while protecting patient privacy. The partnership continued through a $2.3M NIH SBIR grant where Dr. Gibbs served as a collaborator and Geneial's CEO Dr. Adam Hansen was PI. HGSC transitioned registry management to the Xia-Gibbs Society using Geneial's platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

RARE-X is a non-profit-backed rare disease patient data platform that builds federated registries for advocacy groups and offers consented data sharing to researchers and pharma. Most directly comparable to Geneial in target customer (patient advocacy groups), product (registry platform), and data-sharing model — Geneial differentiates on AI ontology mapping and bidirectional REDCap integration.

TypeBroad incumbent
Description

IQVIA operates one of the largest patient registry and real-world data businesses (E360, registry design services) serving pharma and CROs. Comparable as a competitor for pharma/CRO budget and as a benchmark for what scaled registry-plus-analytics offerings look like, though IQVIA does not specialize in rare disease advocacy-group-led registries.

TypeBroad incumbent
Description

DNAnexus provides a cloud genomics and biomedical data platform used by clinical and research organizations, including NIH-funded programs (All of Us, NCI). Comparable to Geneial on genomics data infrastructure and pharma-facing clinical data products, though DNAnexus operates at much larger scale and broader scope.

TypeDirect peer
Description

NORD's IAMRARE platform is a registry infrastructure offered to US rare disease patient advocacy organizations, directly competing for the same PAG customer segment as Geneial. Both serve advocacy groups seeking compliant, easy-to-launch registries, though IAMRARE is non-profit-backed and does not offer AI ontology mapping or REDCap-grade interoperability.

TypeBroad incumbent
Description

TriNetX operates a global health research network aggregating EHR and registry data for clinical trial feasibility and real-world evidence, serving pharma and CRO customers. Comparable to Geneial on pharma-facing clinical data products and federated query, though TriNetX focuses on EHR data and trial site networks rather than patient-reported rare disease registries.

TypeBroad incumbent
Description

Velsera provides a genomics data platform supporting clinical researchers and pharma with data ingestion, harmonization, and analysis workflows. Comparable to Geneial on multi-omics data standardization and pharma/research customer base, though Velsera is positioned more upstream as a sequencing/cloud infrastructure provider.

TypeBroad incumbent
Description

SOPHiA GENETICS operates a genomics data analysis platform used by hospitals and research institutions, with AI-driven variant interpretation. Comparable to Geneial on AI-powered biomedical data interpretation for clinical/research customers and on GA4GH-adjacent data standardization, though SOPHiA focuses on variant calling and clinical reporting workflows.

TypeBroad incumbent
Description

Flatiron Health aggregates oncology EHR and real-world data for pharma and research customers, providing regulatory-grade evidence generation. Comparable to Geneial on regulatory-grade clinical data products for pharma (especially around natural history studies and real-world evidence), though Flatiron is focused exclusively on oncology and is much larger scale.

TypeEmerging player
Description

BC Platforms provides a genomics and biobank data management platform serving pharma and clinical research with federated analytics. Comparable to Geneial on genomic biobank network vision, federated query (similar in spirit to Geneial's FHE work), and pharma-facing rare disease positioning, though BC Platforms is more established in European biobanks.

10RDCA-DAP (Critical Path Institute)
TypeEmerging player
Description

RDCA-DAP is a collaborative rare disease data and analytics platform aggregating standardized data across multiple registries for use in regulatory-grade analyses. Comparable to Geneial on rare-disease data aggregation for FDA submissions and on data standardization mission, though RDCA-DAP is a pre-competitive consortium rather than a commercial platform.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Geneial

Rare Disease Registry Platformgeneial.com

Geneial is a Houston-based health technology company that operates a privacy-preserving rare disease registry platform with bidirectional REDCap integration, AI-powered ontology mapping, and mobile patient engagement, serving patient advocacy groups, academic researchers, and pharma/CROs across 30+ countries.

What Geneial does

Geneial is a Houston, Texas-based health technology company, founded in 2020, that operates a privacy-preserving, decentralized rare disease registry platform connecting patient advocacy groups, academic researchers, and pharmaceutical companies. The company targets the rare disease research market, which encompasses more than 7,000 known conditions affecting roughly 300 million people worldwide, where fewer than 5% have FDA-approved treatments and natural history studies are increasingly required for orphan drug development. Geneial's registries already span 30+ countries and cover 10+ rare diseases, anchored by deployments with the Xia-Gibbs Society (30 countries, 240+ participants) and the HNRNP Family Foundation (an umbrella registry for 10 neurodevelopmental disorders). The company is led by CEO Dr. Adam Hansen and remains privately held with no public revenue disclosure.

The platform is built on two core products and a set of AI modules. Bridge is the registry management interface for researchers and registry managers, offering a survey builder, 21 CFR Part 11-compliant eConsent, participant enrollment tracking, cohort analysis, public statistics dashboards, and bidirectional REDCap integration that allows organizations to upgrade from REDCap without data migration. Advocate is an iOS and Android mobile application for patient communities built around four pillars: Knowledge, Community, Care, and Control, with two-way sync into Bridge. The platform is reinforced by open-source AI tools: GenOMA (an agentic ontology mapping pipeline that converts patient-reported free-text into HPO, SNOMED, and ICD-10 codes with F1 ~0.96), the Geneial Transform Agent (data transformation to GA4GH Phenopackets and LinkML), a UMLS Server for high-performance biomedical terminology access, and synTOPia for privacy-preserving synthetic data generation. Infrastructure is HIPAA, 21 CFR Part 11, SOC 2 Type I, and GDPR compliant and includes a fully homomorphic encryption API for cross-registry queries.

Geneial's commercial model is tiered SaaS subscriptions (Community free, Pro custom-priced, Enterprise custom-priced) with a community-led go-to-market anchored in patient advocacy groups, supplemented by enterprise sales to pharma, CROs, and large academic institutions. A free Contact Registry tier launched in October 2025 extends a product-led growth motion into newly forming advocacy organizations. To date, the company has operated primarily on non-dilutive NIH SBIR funding totaling approximately $2.7M, with strategic relationships including Baylor College of Medicine's Human Genome Sequencing Center, NIH (NHGRI and NHLBI), ARPA-H, RENCI, and a non-binding LOI with NASDAQ-listed Lunai Bioworks.

Geneial firmographics

Firmographics
Name
Geneial
Legal name
Geneial Inc.
Website
https://geneial.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Geneial is a Houston-based health technology company that operates a privacy-preserving rare disease registry platform with bidirectional REDCap integration, AI-powered ontology mapping, and mobile patient engagement, serving patient advocacy groups, academic researchers, and pharma/CROs across 30+ countries.
Ownership category
akta.pro rank

Geneial industry classification

Industry
Product category
Rare Disease Registry Platform
NAICS
Custom Computer Programming Services (541511), Computer Systems Design and Related Services (54151)
SIC
Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370)
akta.pro industry
PRIMARYHLACAIAH
Clinical Data Repositories (CDR) & Longitudinal Patient Records
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare Data Platforms, Warehousing & Governance
SECONDARYHLACAIAG
Consent, Preference & Data Rights Management (incl. HIPAA/GDPR support)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare Data Platforms, Warehousing & Governance
SECONDARYHLACAIAI
FHIR/HL7 Data Repositories & Canonical Data Models
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare Data Platforms, Warehousing & Governance
SECONDARYHLAAANAL
Population Genomics & Preventive Precision Health Programs

Keywords

  • Rare disease registries
  • Patient registry platform
  • Clinical data management
  • Biomedical data standardization
  • Health data interoperability

Where Geneial is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Geneial business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. SaaS Platform Subscriptions (Community, Pro, Enterprise): Geneial generates revenue through tiered SaaS subscription plans. The Community tier is free for organizations starting their first registry. The Pro tier (custom pricing) includes full registry capabilities, REDCap integration, eConsent, unlimited users, and priority support. The Enterprise tier adds dedicated support, custom integrations, advanced analytics, and SLA. Annual billing is implied by custom pricing and demo-first sales motion.

Pricing tiers

ModelBillingPrice
FreemiumMonthlyFree tier for patient advocacy organizations starting their first registry
SubscriptionAnnualCustom-priced tier for organizations running active registries with advanced needs
SubscriptionAnnualCustom enterprise tier for multi-site studies and organizations with complex needs

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Geneial product offering

Product offering

Core offering

Geneial provides a privacy-preserving, decentralized rare disease registry platform consisting of Bridge (a registry management platform for researchers with survey builder, eConsent, cohort analysis, and stats dashboards) and Advocate (a patient-facing mobile app with Knowledge, Community, Care, and Control pillars). The platform integrates bidirectionally with REDCap, enforces HIPAA, 21 CFR Part 11, SOC 2 Type I, and GDPR compliance, and is augmented by proprietary AI tools (GenOMA ontology mapping, Transform Agent, UMLS Server, synTOPia synthetic data) that standardize patient-reported data to FAIR-compliant formats such as GA4GH Phenopackets and HPO codes.

Product overview

Geneial offers a platform-plus-modules architecture for rare disease registries consisting of two core products: Bridge (registry management platform for researchers/registry managers) and Advocate (mobile app for patient communities). These are complemented by AI Tools including GenOMA (ontology mapping agent), Transform Agent (data transformation), UMLS Server (terminology access), and synTOPia (synthetic data generation). The platform supports REDCap integration with bidirectional data sync, enabling organizations to upgrade from REDCap without migration. Pricing tiers include Community (free), Pro (custom), and Enterprise (custom).

Differentiator

Problem solved

Functional benefit

Brands

  • Bridge: Registry command center for building surveys, managing consent, tracking enrollment, and standardizing data. Features include registry builder, eConsent, and statistics dashboard.
  • Advocate
  • GenOMA
  • Geneial Transform Agent
  • UMLS Server
  • synTOPia Data Generator

Products and services

  • Bridge Registry management platform for researchers and registry managers. Provides survey builder, eConsent (21 CFR Part 11), participant enrollment tracking, cohort analysis, HPO/HGVS code mapping, variant visualization, and stats dashboards. Integrates bidirectionally with REDCap and supports FAIR-compliant data standards.
  • Advocate

Quantifiable outcome

  • Registry deployment reduced from months to under one week using enhanced GenomeConnect survey with conditional logic and free-text fields
  • +4 more outcomes

Companies that use Geneial

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Geneial technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability8 records

Feature9 records

Geneial partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and flagship.

  • Lunai Bioworks (via BioSymetrics subsidiary)coreStrategic or Co-development Partner · 16 April 2026BioSymetrics (wholly owned subsidiary of NASDAQ-listed Lunai Bioworks) signed a non-binding LOI with Geneial for a strategic collaboration focused on rare neurological disorders. The collaboration aims to convert fragmented patient-generated data into trial-ready cohorts for pharmaceutical partnerships. Data across multiple patient registries and longitudinal clinical data will be integrated to support cohort development and translational research. Specific commercial terms to be defined in future definitive agreements.
  • HNRNP Family FoundationcoreStrategic or Co-development Partner · 5 November 2024HNRNP Family Foundation partnered with Geneial for an umbrella registry covering 10 HNRNP-Related Neurodevelopmental Disorders (HNRNP-RNDDs). The partnership enables collection, curation, and analysis of complex data across multiple genes, research sites, and data sources. Geneial's team also supported the foundation in writing grant applications, demonstrating deep collaborative partnership beyond software provision.
  • NIH (National Institutes of Health) / NHGRIcoreOthers · 1 November 2023Geneial received NIH funding through multiple grants: $2.3M SBIR grant (September 2022, NHGRI), Phase II SBIR grant (July 2023), and Phase I SBIR award for pharmacogenomics platform (November 2023). Total NIH funding exceeds $2.7M. NIH grants fund development of privacy-preserving, decentralized platform for genetic disease research and pharmacogenomics applications.
  • ARPA-H (Advanced Research Projects Agency for Health)flagshipStrategic or Co-development Partner · 1 November 2023Geneial was awarded a one-year pilot project through NHLBI BioData Catalyst (BDC) program and RENCI to partner with ARPA-H Biomedical Data Fabric (BDF) Toolbox program. Collaboration aims to advance AI tools that automate transformation of biomedical data into analysis-ready formats, supporting GA4GH Phenopackets standards. CEO Dr. Adam Hansen noted the partnership directly addresses data standardization bottlenecks in precision medicine.
  • RENCI (Renaissance Computing Institute)flagshipStrategic or Co-development Partner · 1 November 2023RENCI collaborates with Geneial on a one-year pilot project through NHLBI BioData Catalyst program, partnering with ARPA-H. RENCI develops and deploys advanced technologies to enable research discoveries. The collaboration focuses on AI-driven biomedical data standardization at scale.
  • NHLBI BioData Catalyst (BDC)flagshipStrategic or Co-development Partner · 1 November 2023National Heart, Lung, and Blood Institute's BioData Catalyst program awarded Geneial a one-year pilot project alongside RENCI and ARPA-H to advance AI tools for biomedical data standardization and interoperability.
  • Xia-Gibbs SocietycoreStrategic or Co-development Partner · 26 October 2023Xia-Gibbs Society deployed Geneial Bridge and Advocate for their global rare disease community. The society, led by Executive Director Greg Wilkinson, manages a registry spanning 30 countries covering families affected by Xia-Gibbs Syndrome (AHDC1 gene variants). Geneial replaced a REDCap-based system managed by Baylor College of Medicine HGSC.
  • Baylor College of Medicine - Human Genome Sequencing Center (HGSC)coreStrategic or Co-development Partner · 12 January 2022Geneial partnered with BCM-HGSC led by Dr. Richard Gibbs to establish a proof-of-concept for privacy-preserving data exchange using the Xia-Gibbs Syndrome registry. Successfully demonstrated advanced encryption enabling exact-match querying while protecting patient privacy. The partnership continued through a $2.3M NIH SBIR grant where Dr. Gibbs served as a collaborator and Geneial's CEO Dr. Adam Hansen was PI. HGSC transitioned registry management to the Xia-Gibbs Society using Geneial's platform.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Geneial competitors and assessment

Company assessment

Direct peers

  • RARE-X: RARE-X is a non-profit-backed rare disease patient data platform that builds federated registries for advocacy groups and offers consented data sharing to researchers and pharma. Most directly comparable to Geneial in target customer (patient advocacy groups), product (registry platform), and data-sharing model — Geneial differentiates on AI ontology mapping and bidirectional REDCap integration.
  • NORD (National Organization for Rare Disorders) IAMRARE Registry: NORD's IAMRARE platform is a registry infrastructure offered to US rare disease patient advocacy organizations, directly competing for the same PAG customer segment as Geneial. Both serve advocacy groups seeking compliant, easy-to-launch registries, though IAMRARE is non-profit-backed and does not offer AI ontology mapping or REDCap-grade interoperability.

Broad incumbents

  • IQVIA: IQVIA operates one of the largest patient registry and real-world data businesses (E360, registry design services) serving pharma and CROs. Comparable as a competitor for pharma/CRO budget and as a benchmark for what scaled registry-plus-analytics offerings look like, though IQVIA does not specialize in rare disease advocacy-group-led registries.
  • DNAnexus: DNAnexus provides a cloud genomics and biomedical data platform used by clinical and research organizations, including NIH-funded programs (All of Us, NCI). Comparable to Geneial on genomics data infrastructure and pharma-facing clinical data products, though DNAnexus operates at much larger scale and broader scope.
  • TriNetX: TriNetX operates a global health research network aggregating EHR and registry data for clinical trial feasibility and real-world evidence, serving pharma and CRO customers. Comparable to Geneial on pharma-facing clinical data products and federated query, though TriNetX focuses on EHR data and trial site networks rather than patient-reported rare disease registries.
  • Velsera (formerly Seven Bridges): Velsera provides a genomics data platform supporting clinical researchers and pharma with data ingestion, harmonization, and analysis workflows. Comparable to Geneial on multi-omics data standardization and pharma/research customer base, though Velsera is positioned more upstream as a sequencing/cloud infrastructure provider.
  • SOPHiA GENETICS: SOPHiA GENETICS operates a genomics data analysis platform used by hospitals and research institutions, with AI-driven variant interpretation. Comparable to Geneial on AI-powered biomedical data interpretation for clinical/research customers and on GA4GH-adjacent data standardization, though SOPHiA focuses on variant calling and clinical reporting workflows.
  • Flatiron Health: Flatiron Health aggregates oncology EHR and real-world data for pharma and research customers, providing regulatory-grade evidence generation. Comparable to Geneial on regulatory-grade clinical data products for pharma (especially around natural history studies and real-world evidence), though Flatiron is focused exclusively on oncology and is much larger scale.

Emerging players

  • BC Platforms: BC Platforms provides a genomics and biobank data management platform serving pharma and clinical research with federated analytics. Comparable to Geneial on genomic biobank network vision, federated query (similar in spirit to Geneial's FHE work), and pharma-facing rare disease positioning, though BC Platforms is more established in European biobanks.
  • RDCA-DAP (Critical Path Institute): RDCA-DAP is a collaborative rare disease data and analytics platform aggregating standardized data across multiple registries for use in regulatory-grade analyses. Comparable to Geneial on rare-disease data aggregation for FDA submissions and on data standardization mission, though RDCA-DAP is a pre-competitive consortium rather than a commercial platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Geneial social profiles

Digital presence

Geneial compliance and trust

Trust signal

Compliance4 records

Geneial financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Geneial leadership team

Management profile

Number of profiles

Profiles3 records

Geneial funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Geneial M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Geneial

What does Geneial do?

Geneial provides a privacy-preserving, decentralized rare disease registry platform consisting of Bridge (a registry management platform for researchers with survey builder, eConsent, cohort analysis, and stats dashboards) and Advocate (a patient-facing mobile app with Knowledge, Community, Care, and Control pillars). The platform integrates bidirectionally with REDCap, enforces HIPAA, 21 CFR Part 11, SOC 2 Type I, and GDPR compliance, and is augmented by proprietary AI tools (GenOMA ontology mapping, Transform Agent, UMLS Server, synTOPia synthetic data) that standardize patient-reported data to FAIR-compliant formats such as GA4GH Phenopackets and HPO codes.

Is Geneial a public or private company?

Geneial is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Geneial founded?

Geneial was founded in 2020. It employs 1 to 10 people.

Where is Geneial based?

Geneial is headquartered in Houston, United States, in the North America region.

How does Geneial make money?

One revenue line is on record: saaS Platform Subscriptions (Community, Pro, Enterprise).

Who are Geneial's main competitors?

Direct peers on record are RARE-X and NORD (National Organization for Rare Disorders) IAMRARE Registry. Broad incumbents are IQVIA, DNAnexus, TriNetX, Velsera (formerly Seven Bridges), SOPHiA GENETICS and Flatiron Health. Emerging players are BC Platforms and RDCA-DAP (Critical Path Institute).

Does Geneial have an API?

Yes. Geneial integrates with REDCap via its API (read/write bidirectional sync). The platform also offers a Fully Homomorphic Encryption (FHE) API for private information retrieval in pharmacogenomics applications, enabling privacy-preserving queries on genomic data without exposing individual records. Additional open-source tools available on GitHub include Geneial Transform Agent, GenOMA (Ontology Mapping Agent), UMLS Server, and synTOPia Data Generator. Developer documentation is at github.com/geneialco.

What industry is Geneial in?

Geneial's product category is Rare Disease Registry Platform. Its primary akta.pro industry code is HLACAIAH, Clinical Data Repositories (CDR) & Longitudinal Patient Records, with a secondary code of HLACAIAG, Consent, Preference & Data Rights Management (incl. HIPAA/GDPR support). Its NAICS code is 541511 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceLunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma PartnershipsLunai Bioworks' wholly owned subsidiary BioSymetrics has signed a non-binding Letter of Intent with Geneial to pursue a strategic collaboration focused on rare neurological disorders, aimed at converting fragmented patient-generated data into trial-ready cohorts for pharmaceutical partnerships. The collaboration will integrate datasets across multiple patient registries and longitudinal clinical data to support cohort development and translational research. The LOI is preliminary and specific commercial terms will be defined in future definitive agreements, with expected revenue-generating partnerships with pharmaceutical and biotechnology companies.Investing.comLunai Bioworks signs letter of intent with Geneial for rare disease data collaboration By Investing.comLunai Bioworks' subsidiary BioSymetrics has signed a non-binding letter of intent with Geneial, Inc. to pursue a collaboration focused on rare neurological disorders, aiming to convert patient-generated data into structured datasets for drug development and clinical trial recruitment. The companies plan to integrate data across multiple patient registries and create trial-ready cohorts for potential pharmaceutical partnerships, though specific projects and commercial terms will be defined in future definitive agreements. The announcement comes as Lunai Bioworks, with a market capitalization of $8.19 million, has seen its stock decline over 90% over the past year and is burning through cash, highlighting the strategic importance of the collaboration for the struggling AI-driven biotech.Stock TitanLunai Bioworks signs Geneial rare disease LOILunai Bioworks subsidiary BioSymetrics signed a non-binding Letter of Intent with Geneial to collaborate on building trial-ready patient cohorts for rare neurological disorders to support pharmaceutical drug development partnerships. The collaboration aims to convert fragmented patient-generated data into structured datasets that can accelerate clinical development, targeting a multi-billion dollar market serving approximately 300 million people globally affected by rare diseases. The companies expect to pursue commercial partnerships enabled by these efforts, though specific projects and terms will be defined in future definitive agreements.PR NewswireLunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma PartnershipsLunai Bioworks subsidiary BioSymetrics has signed a non-binding Letter of Intent with Geneial to pursue a strategic collaboration focused on converting patient-generated data into trial-ready cohorts for rare neurological disorders. The collaboration aims to integrate datasets across multiple patient registries and enable commercial partnerships with pharmaceutical companies. The LOI is preliminary in nature, with specific projects and commercial terms expected to be defined in future definitive agreements.PR NewswireGeneial Secures Major Contract with RENCI and NHLBI to Partner with ARPA-H to Transform Biomedical Data Standardization with Advanced AIGeneial, a genetic medicine company, has been awarded a one-year pilot project in partnership with RENCI, NHLBI's BioData Catalyst program, and ARPA-H's Biomedical Data Fabric Toolbox program to develop AI tools for standardizing biomedical data into analysis-ready formats. The technology will automate conversion to standards like GA4GH Phenopackets, reducing manual effort and costs while addressing a key bottleneck in precision medicine research. This marks Geneial's strategic expansion into generative AI and aligns with its vision of a privacy-preserving global data exchange for genomic medicine.PR NewswireGeneial Receives New NIH Grant For Private Pharmacogenomics WorkflowGeneial received a Phase I SBIR grant from the NIH National Library of Medicine to expand its privacy-preserving genetic data platform into pharmacogenomics. The funding will support the engineering of a proof-of-concept that allows for patient-specific dosage recommendations without exposing underlying whole genome sequencing data. This initiative aims to address barriers to widespread clinical adoption by giving individuals granular control over their genomic information.PRESSBEEGeneial Receives New NIH Grant For Private Pharmacogenomics Workflow ...Middle EastGeneial has been awarded a grant by the NIH to enhance its privacy-preserving genetic data platform specifically for pharmacogenomics. This initiative aims to address the ongoing challenges related to privacy and data ownership in the genetic testing field.LuminewsGeneial Receives New NIH Grant For Private Pharmacogenomics WorkflowGeneial, a HealthTech startup based in Houston, received a new grant from the NIH National Library of Medicine to expand its privacy-preserving genetic data platform into pharmacogenomics. This funding aims to address barriers to the widespread clinical implementation of pharmacogenomics by enhancing the company's existing capabilities. The initiative follows Geneial's recent launch of a platform for rare disease registries.PR NewswireGeneial Receives $2.3M NIH GrantHouston-based healthtech company Geneial announced on September 22, 2022 a $2.3 million non-dilutive award from the National Human Genome Research Institute to build a secure, decentralized platform for exchanging rare genetic disease data while preserving patient privacy. The award is part of a highly selective Small Business Transition Grant for Early Career Scientists program with fewer than ten companies funded to date.